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PERSPECTIVES ON DRUGS 
Synthetic cannabinoids 
in Europe
Synthetic cannabinoid receptor agonists (commonly referred 
to as ‘synthetic cannabinoids’) are a group of substances 
that mimic the effects of (–)-trans-Δ9-tetrahydrocannabinol 
(THC), which is the substance that is primarily responsible 
for the major psychoactive effects of cannabis. Like THC, the 
synthetic cannabinoids bind to the cannabinoid receptors 
in the body. This is why these substances have been used 
to create a large range of ‘legal high’ products sold as legal 
replacements for cannabis. They are the largest group of 
new psychoactive substances monitored by the European 
Monitoring Centre for Drugs and Drug Addiction (EMCDDA).
‘Legal high’ products containing synthetic cannabinoids have 
been sold as ‘herbal smoking mixtures’ since the mid-2000s. 
These products do not contain cannabis, but when smoked 
produce similar effects. They have been subject to innovative 
marketing approaches and are widely and openly available on 
the web, and in some countries in bricks-and-mortar (‘head’ 
and ‘smart’) shops.
The number of synthetic cannabinoids, their chemical 
diversity and the speed of their emergence make this group 
of compounds particularly challenging in terms of detection, 
monitoring, and responding. Suppliers simply aim to mimic 
the effects of THC. In essence, this makes each synthetic 
cannabinoid disposable. When one synthetic cannabinoid is, 
or is about to be, legally controlled manufacturers can have 
one or more replacement substance ready for sale.
Little is known about how these substances work and their 
toxic effects in humans. However, their use has caused many 
serious poisonings and even deaths — sometimes these have 
manifested as outbreaks of mass poisonings. It is possible 
that, along with being highly potent, some may also have long 
half-lives, potentially leading to a prolonged psychoactive 
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effect. In addition, it appears that at least some of these 
substances have an effect on other physiological functions in 
the body beyond effects on the cannabinoid receptors.
This analysis aims to provide an update on the current 
knowledge of these substances and their effects, and trends 
in production, availability and use.
I  The emergence of synthetic cannabinoids
Despite internet rumours since the mid-2000s of ‘herbal 
smoking mixtures’ sold as ‘legal highs’ that could produce 
‘strong’ cannabis-like effects, it wasn’t until 2008 that forensic 
investigators in Germany and Austria first detected the 
synthetic cannabinoid JWH-018, in a product sold under 
the brand name ‘Spice’. Subsequently several cannabinoids 
were detected in smoking mixtures or so-called incense/
room odorisers. Typical of these were Spice Gold, Spice Silver 
and Yucatan Fire, but many other products later appeared. 
Many of the cannabinoids that have been detected in these 
products were first developed by scientists investigating how 
cannabinoids affect the body and to see if they could work as 
medicines to treat a number of diseases and their symptoms 
— such as neurodegenerative diseases, drug dependence, 
pain disorders and cancer. However, so far it has proved 
difficult to separate the desired medicinal properties from 
unwanted psychoactive effects.
Synthetic cannabinoids represent the largest group of 
substances currently monitored by the EU Early Warning 
System. One was reported in 2008; 9 in 2009; 11 in 2010; 
23 in 2011; 30 in 2012; 29 in 2013; 30 in 2014; 25 in 2015; 
and 11 in 2016 — with a total of 169 synthetic cannabinoids 
having been notified to the EMCDDA as of December 2016 
(1).
Synthetic cannabinoids play an important role in the rapidly 
evolving ‘legal highs’ market. ‘Legal highs’ is an umbrella 
term used to describe non-regulated (new) psychoactive 
substances that are usually intended to mimic the effects 
of controlled drugs and are sold on the open market. This is 
an area characterised by limited data on use, with the risks 
and harms largely unknown, and where highly potent drugs 
are of serious concern. In the case of smoking mixtures 
containing synthetic cannabinoids, for example, there can 
be considerable variability both within and between different 
batches of the products, in terms of both the substances and 
the amount present.
I  The manufacture of synthetic cannabinoid products
Most of the synthetic cannabinoids that are used in ‘legal 
high’ products are manufactured by chemical companies 
based in China. They are shipped as bulk powders to Europe 
using express mail and courier companies; larger amounts 
may be shipped by air or sea cargo. Multi-kilogram shipments 
are frequently intercepted by authorities in Europe. While 
the purity of these bulk powders are rarely determined, one 
study from South Korea reported purities of between 75 % 
and 90 % for bulk powder samples. In 2015 over 24 000 
seizures of synthetic cannabinoids (24 210) were made in 
Europe weighing more than 2.3 tonnes (2 334 kg), of which 
over 400 kg (444.245 kg) was bulk powder. This represents 
an increase of almost 7 000 seizures and over 1.6 tonnes 
(mostly consisting of plant material) compared to 2014. 
Once in Europe, the retail products are put together. Damiana 
(Turnera diffusa) and Lamiaceae herbs such as Melissa, 
Mentha and Thymus are commonly used as the plant base 
for the smoking mixtures. The synthetic cannabinoids are 
mixed with or sprayed onto the plant material, typically on an 
industrial scale using solvents such as acetone or methanol 
to dissolve the powders; equipment like cement mixers are 
then used to mix the ingredients together. From there, the 
mixture is then dried and packaged. They are then sold on the 
internet by ‘legal high’ retailers and in bricks-and-mortar head 
shops.
Due to the high potency of some synthetic cannabinoids, 
the amount of powder needed for each packet can be in 
the order of a few tens of milligrams. This means that each 
kilogram of bulk powder may produce thousands of packets 
of ‘legal highs’. The discovery of processing and packaging 
facilities and large quantities of synthetic cannabinoids in 
the Netherlands and Belgium suggests the involvement of 
(1 ) For the purposes of monitoring within the framework of the EU Early Warning System, the term ‘synthetic cannabinoids’ is used here to include: the large number of 
synthetic cannabinoid receptor agonists (such as JWH-018 which is a CB1 and CB2 receptor agonist) that have been detected on the European drug market; a much smaller 
number of allosteric modulators (such as Org 27569) that change the structure of the cannabinoid receptors leading to altered activity when a ligand binds to the receptors; 
and substances that act as inhibitors of fatty-acid amide hydrolase (FAAH), which is the enzyme responsible for breaking down the endocannabinoid anandamide (such as 
URB597). This Perspective on Drugs only discusses the synthetic cannabinoid receptor agonists.
.
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organised crime in the distribution process. There is also 
evidence of a significant internet retail trade within Europe, 
with customs and police making regular seizures of small 
quantities of these products.
Monitoring of online shops selling ‘legal high’ products 
provides some insight into the range of smoking mixtures 
available for purchase, many of which are likely to contain 
synthetic cannabinoids. Such monitoring, when combined 
with test purchasing of products for sale, is also a way of both 
keeping track of how the substances contained in a product 
change over time, and helping in the early detection of new 
cannabinoids that appear on the market.
I  Prevalence
Information on the extent to which synthetic cannabinoid 
products are used is limited; however, knowledge of the 
situation is improving as more countries incorporate 
questions about their use in general population surveys. 
From the information that is available, it would appear that 
the prevalence of their use in the general population is low 
in Europe. A number of surveys aimed at examining the 
prevalence of use of ‘Spice’-like products have been launched 
but their coverage and representativeness remains limited.
There are notable differences between the prevalence of use 
of synthetic cannabinoid products between the European and 
US drug markets. The most recent US prevalence data comes 
from the 2014 US Monitoring the Future survey of students, 
which suggests use is declining, with last year prevalence 
for 17- to 18-year-olds of 5.8 % in 2014, down from 7.9 % in 
2013 and 11.3 % in 2012. In 2011, according to the same 
survey, ‘synthetic marijuana’ was the second most widely 
used drug after cannabis, with last year prevalence of 11.4 %. 
A number of surveys in European countries also report on 
the use of synthetic cannabinoids, although they are not 
comparable as they use different methods, sampling frames 
and terminology. Overall, these studies indicate very low 
prevalence levels. The United Kingdom (England and Wales) 
asked about the use of ‘Spice’ in two consecutive household 
surveys and reported lifetime prevalence levels for adults 
(16–64) at 0.2 % in 2010/2011 and 0.1 % in 2011/2012. 
In the British Crime Survey for England and Wales covering 
2014/2015 a total of 0.9 % of adults (16–59) had used new 
psychoactive substances in the last year, of which 61 % 
had used a herbal smoking mixture. The question was not 
repeated in subsequent years due to the low prevalence rate. 
In Spain a 2014 national survey on drug use among students 
aged 14–18 with a sample of 37 486 identified low levels 
of use of ‘Spice’ products, with prevalence rates of 0.8 % in 
2014 for lifetime use, down from 1.4 % in 2012 and 1.1 % in 
2010. In a general population survey conducted in 2013 also 
in Spain, 0.5 % of the 23 136 respondents (aged 15 to 64) 
reported lifetime use of Spice. 
A 2014 French survey of adults (18–64) with a question 
about the use of ‘synthetic cannabinoids’ reported lifetime 
use of 1.7 %. First-time users of these new synthetic products 
are mostly males (2.3 % vs. 1.2 % of females) and from 
the youngest generation (under 35 years): 4.0 % of 18- to 
34-year-olds had tried synthetic cannabinoid compared to 
0.6 % of 35- to 64-year-olds. Another survey in France, among 
young people aged 17, reported that 1.7 % of them have 
previously used a synthetic cannabinoid. 
The Swedish Council for Information on Alcohol and Other 
Drugs (CAN) 2015 survey asked students about their 
consumption of new psychoactive substances. It found a 
decrease compared to other years in the 9th and 11th grades, 
I  Facts and figures 
Over 620 new psychoactive substances are currently 
monitored by the EMCDDA through the EU Early Warning 
System, 169 of which are synthetic cannabinoid receptor 
agonists.
14 recognisable chemical families of synthetic cannabinoids 
are known
2008 — JWH-018 was the first synthetic cannabinoid to be 
detected in a ‘legal high’ product
Interactive: demystifying the chemistry:  
emcdda.europa.eu/topics/pods/synthetic-cannabinoids
I  Interactive
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with 1.6 % and 3.2 % respectively reporting use at some 
stage. Synthetic cannabinoids were the most commonly used 
new psychoactive substance reported by those in the 9th 
grade and the second year of upper secondary school. 
The German city of Frankfurt has studied the use of smoking 
mixtures and ‘Spice’ among students aged 15–18. They 
reported lifetime levels of use of 7 % in 2009; 9 % in 2010; 
and 7 % in 2011 and 2012. In 2013 lifetime use of smoking 
mixtures fell to 5 %, but increased to 6 % in 2014 and 
remained at 6 % in 2015; however, this is still below the 
values from 2009–12. Students reporting the consumption 
of ‘Spice’ were, for the most part, experienced cannabis 
consumers. 
Finally, a number of studies among particular groups 
(clubbers, internet users, etc.) with non-probabilistic 
samples have generally identified higher levels of synthetic 
cannabinoid use than among the general population. The 
2012 Global Drug Survey, for example, reported last year 
prevalence levels of 3.3 % among all UK respondents (not 
representative of the general population) and 5.0 % among 
UK regular clubbers.
In the United Kingdom, use of synthetic cannabinoids among 
prisoners is of particular concern.  A  survey conducted in 
2016 in the United Kingdom’s prisons found 33 % of the 625 
inmates reported the use of ‘Spice’ within the last month (this 
compares to 14 % of last month cannabis use). Variation in 
the prevalence levels of ‘Spice’ use within the last month from 
prison to prison ranged from 15 % to 71 %. Those individuals 
who had used ‘Spice’ within the last month, were asked 
about the weekly frequency of use; results showed that 31 % 
had used ‘Spice’ once or twice a week, 8 % once a week, 
15 % 2-3 times a week and 46 % almost daily. A previous 
study conducted in 2015 by the HM Inspectorate Prisons 
interviewed 1 376 prisoners in eight prisons and found that 
10 % were using ‘Spice’ in their respective prison.
I  Synthetic cannabinoid related harms
The adverse health effects associated with synthetic 
cannabinoids are linked to both the intrinsic properties of 
the substances, what the body does to the substances, 
and to the way the products are produced. There has been 
a large number of non-fatal poisonings, and a smaller 
number of deaths are associated with their use. As some 
of these compounds are very potent, the potential for toxic 
effects appears to be high. These risks may be added to by 
the manufacturing process, which can lead to an uneven 
distribution of the substances within the plant material. This 
may result in some products containing ‘hot pockets’ where 
the cannabinoid is highly concentrated, leading to doses that 
are higher than intended and increasing the risk of serious 
adverse events. It is also possible that some of the adverse 
effects are due to mechanisms other than interaction with the 
cannabinoid receptors, for example by interfering with other 
physiological functions in the body.
A recent systematic review of adverse events associated with 
synthetic cannabinoid products found that agitation, nausea 
and an abnormally fast, racing heartbeat were frequently 
reported poisoning symptoms; while serious adverse events 
— such as stroke, seizure, heart attack, breakdown of muscle 
tissue, kidney damage, psychosis and severe or prolonged 
vomiting — and associated deaths were less common. 
Symptoms suggestive of dependence and withdrawal have 
also been reported. Overall, estimating how common these 
adverse events are is difficult because, among other things, 
the total number of people exposed to the drugs is unknown. 
One of the most striking features of synthetic cannabinoid 
products is their ability to cause outbreaks of mass 
poisonings. Sometimes this involves hundreds of people over 
a short period of time — which has been a major problem in 
the past few years in the United States and Russia. In 2014 
in Russia the cannabinoid MDMB-FUBINACA was linked 
to more than 600 poisonings, including 15 deaths, over a 
two-week period. Early in 2016 this substance was identified 
on the European market, triggering a public health alert from 
the EMCDDA to its early warning network. In 2015 there was 
another large outbreak in the United States, which appears 
to have been linked partly to a substance called ADB-
FUBINACA. While these types of outbreaks appear to be rare 
in Europe, in 2015 more than 200 hospital emergencies were 
reported in less than a week after people were reported to 
have smoked a product called ‘Mocarz’ in Poland.
In July 2016, MDMB-CHMICA was the first synthetic 
cannabinoid receptor agonist to be risk-assessed by the 
EMCDDA and it has recently been subjected to control 
measures and criminal penalties throughout Europe. MDMB-
CHMICA is classed as a potent and full agonist at the CB1 
receptor and has also been shown to be an agonist at the 
CB2 receptor. At the time of the risk assessment, 25 acute 
intoxications and 28 deaths associated with MDMB-CHMICA 
had been reported to the EMCDDA. In 12 of the cases, 
MDMB-CHMICA was reported as, either the cause of, or 
likely to have contributed to, the death.  In three cases, it 
was the only substance detected. MDMB-CHMICA has been 
available on the European Union drug market since at least 
August 2014, and, at the time of the risk assessment, it had 
been detected in 23 Member States, Turkey and Norway. 
Information reported to the EMCDDA and Europol indicated 
that over 120 kg of MDMB-CHMICA had been seized with 
approximately 67 kg as herbal material and approximately 
46 kg in powder form. The largest single bulk seizure reported 
to the EMCDDA, which was 40 kg of highly pure powder 
containing MDMB-CHMICA, originated in China. 
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EMCDDA monitoring of serious adverse events and current 
knowledge of the pharmacological and toxicological effects 
of some synthetic cannabinoids, show that these compounds 
can cause serious harm to human health. However, at present 
the mechanisms of how this happens are poorly understood.
I  Recent developments
From the start of the synthetic cannabinoid phenomenon 
these substances have largely been detected in products sold 
as ‘herbal smoking mixtures’. More recently, however, several 
countries have also reported finding the substances in 
products that look like cannabis resin, either in branded ‘legal 
high’ products such as ‘Afghan Incense’ or simply passed 
off as cannabis resin on the illicit market. This development 
is likely to be a response to the popularity of cannabis resin 
in many countries. Synthetic cannabinoids have also been 
detected in mixtures containing other new psychoactive 
substances, such as stimulants, hallucinogens and sedative/
hypnotics; this may be deliberate or accidental. In a small 
number of cases, the presence of synthetic cannabinoids 
has been detected in what appear to be ecstasy tablets or 
capsules. In Hungary and the United States this has led to 
clusters of acute poisonings. Another recent development has 
been the discovery of synthetic cannabinoids in the liquid-
filled cartridges for use in electronic cigarettes; this most 
likely reflects the recent popularity of ‘vaping’ among young 
people.
The EMCDDA has been closely monitoring developments 
relating to synthetic cannabinoids since their identification 
on the European market in 2008. A striking feature has 
been the way in which this chemical family has evolved 
and adapted during this time. It is clear that the innovative 
chemical substitution patterns that have characterised this 
phenomenon mean that continued close monitoring of new 
developments in the field — including synthetic cannabinoid-
related harms — will be essential. 
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Many of the synthetic cannabinoids monitored by the 
EMCDDA through the EU Early Warning System have code 
names that relate to their discovery. In some cases they 
are derived from the initials of the name of the scientists 
that first synthesised them: e.g. ‘JWH’ compounds after 
John W. Huffman and ‘AM’ compounds after Alexandros 
Makriyannis. In other cases code names may originate 
from the institution or company where they were first 
synthesised, the ‘HU’ series of synthetic cannabinoids 
being from the Hebrew University in Jerusalem, or ‘CP’ 
from Carl Pfizer. In some cases names have probably 
been chosen by those making ‘legal high’ products to 
help market the products. Striking examples of this are 
‘AKB-48’ and ‘2NE1’, alternative names used for APINACA 
and APICA. ‘AKB-48’ is the name of a popular Japanese 
girl band and ‘2NE1’ is the name of a girl band from South 
Korea. Finally, the synthetic cannabinoid XLR-11, appears 
to have been named after the first liquid fuel rocket 
developed in the USA for use in aircraft, perhaps alluding 
to the vendor’s intention for those who consume the 
substance.  
 
Many synthetic cannabinoids are now given code names 
that are derived from their long chemical names, such 
as APICA from N-(1-adamantyl)-1-pentyl-1H-indole- 
3-carboxamide, and APINACA from N-(1-adamantyl)-1-
pentyl-1H-indazole-3-carboxamide. The EMCDDA has 
systematised this method in order to apply it to newly 
emerging substances and show how the various constituent 
parts can be put together. The structures of many synthetic 
cannabinoids can be categorised into four components: tail, 
core, linker and linked group. Assigning each component 
a code name allows the chemical structure of the 
cannabinoid to be identified without the long chemical 
name. The proposed naming syntax for the synthetic 
cannabinoids that follow this pattern is as follows: 
LinkedGroup – TailCoreLinker
Ordering the components in this manner follows the 
ordering as seen in their longer chemical names, as 
with  APICA: N-(1-adamantyl)-1-pentyl-1H-indole-3-
carboxamide. When a tail substituent is present (i.e. 5F) this 
will be displayed at the front of the name and linked group 
substituents will be placed before the linked group; core 
substituents will be placed at the end of the code. 
 















Current name: AB-FUBINACA  
New name: MABO-FUBINACA 
 
The letter codes used are based not only on the letter 
used but also on the ordering of letters. For example, A 
identifies the amine in the linked group; CA identifies the 
carboxamide. By following the syntax and codes described, 
synthetic cannabinoids that follow this structure will have a 
unique short name.  
 
Visit the POD website for more information:  
www.emcdda.europa.eu/topics/pods/synthetic-
cannabinoids 
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